PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia.

Abstract Resistance in the sexually transmitted bacterium Mycoplasma genitalium to all recommended therapeutic antimicrobials have rapidly emerged. However, to date, internationally reported resistance surveillance data for M. genitalium strains circulating in Eastern Europe are entirely lacking. The aim of this study was to estimate the prevalence of macrolide and fluoroquinolone resistance-associated mutations in M. genitalium in four cities in Russia and one in Estonia, 2013-2016.
PMID
Related Publications

Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium.

High levels of macrolide resistance-associated mutations in Mycoplasma genitalium warrant antibiotic susceptibility-guided treatment.

Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin.

Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance.

Remarkable increase in fluoroquinolone-resistant Mycoplasma genitalium in Japan.

Authors

Mayor MeshTerms

Drug Resistance, Bacterial

Mutation

Keywords
Journal Title plos one
Publication Year Start




PMID- 28407014
OWN - NLM
STAT- MEDLINE
DA  - 20170413
DCOM- 20170420
LR  - 20170420
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 4
DP  - 2017
TI  - Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in
      Mycoplasma genitalium in five cities in Russia and Estonia.
PG  - e0175763
LID - 10.1371/journal.pone.0175763 [doi]
AB  - BACKGROUND AND OBJECTIVE: Resistance in the sexually transmitted bacterium
      Mycoplasma genitalium to all recommended therapeutic antimicrobials have rapidly 
      emerged. However, to date, internationally reported resistance surveillance data 
      for M. genitalium strains circulating in Eastern Europe are entirely lacking. The
      aim of this study was to estimate the prevalence of macrolide and fluoroquinolone
      resistance-associated mutations in M. genitalium in four cities in Russia and one
      in Estonia, 2013-2016. MATERIALS AND METHODS: Consecutive urogenital samples
      found positive for M. genitalium during diagnostic testing were retrospectively
      analyzed for resistance-associated mutations in the 23S rRNA and parC genes using
      pyrosequencing and conventional Sanger sequencing, respectively. RESULTS: In
      total, 867 M. genitalium positive samples from 2013-2016 were analyzed. Macrolide
      resistance-associated mutations were detected in 4.6% of the samples from Russia 
      (0.7-6.8% in different cities) and in 10% of the samples from Estonia. The
      mutations A2059G and A2058G were highly predominating in both Russia and Estonia,
      accounting together for 90.9% of the cases positive for nucleotide substitutions 
      in the 23S rRNA gene. The rates of possible fluoroquinolone resistance-associated
      mutations were 6.2% in Russia (2.5-7.6% in different cities) and 5% in Estonia.
      The mutations S83I and S83N were the most frequent ones in Russia (24.4% each),
      whereas D87N highly predominated in Estonia (83.3% of all fluoroquinolone
      resistance-associated mutations). Approximately 1% of the samples in both
      countries harbored both macrolide and possible fluoroquinolone
      resistance-associated mutations, with A2058G and S83I being the most frequent
      combination (37.5%). CONCLUSIONS: The prevalence of macrolide and fluoroquinolone
      resistance-associated mutations in M. genitalium was 4.6% and 6.2%, respectively,
      in Russia, and 10% and 5%, respectively, in Estonia. Despite the relatively low
      rates of macrolide and fluoroquinolone resistance in these countries,
      antimicrobial resistance surveillance and testing for resistance-associated
      mutations in M. genitalium positive cases would be valuable.
FAU - Shipitsyna, Elena
AU  - Shipitsyna E
AD  - Laboratory of Microbiology, D.O. Ott Research Institute of Obstetrics,
      Gynaecology and Reproductology, St. Petersburg, Russia.
AD  - WHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory 
      Medicine, Faculty of Medicine and Health, Orebro University, Orebro, Sweden.
FAU - Rumyantseva, Tatiana
AU  - Rumyantseva T
AD  - Laboratory of Molecular Diagnostics, Central Research Institute of Epidemiology, 
      Moscow, Russia.
FAU - Golparian, Daniel
AU  - Golparian D
AD  - WHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory 
      Medicine, Faculty of Medicine and Health, Orebro University, Orebro, Sweden.
FAU - Khayrullina, Guzel
AU  - Khayrullina G
AD  - Laboratory of Molecular Diagnostics, Central Research Institute of Epidemiology, 
      Moscow, Russia.
FAU - Lagos, Amaya C
AU  - Lagos AC
AD  - WHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory 
      Medicine, Faculty of Medicine and Health, Orebro University, Orebro, Sweden.
FAU - Edelstein, Inna
AU  - Edelstein I
AD  - Institute of Antimicrobial Chemotherapy, Smolensk State Medical University,
      Smolensk, Russia.
FAU - Joers, Kai
AU  - Joers K
AD  - United Laboratories, Tartu University Hospital, Tartu, Estonia.
FAU - Jensen, Jorgen S
AU  - Jensen JS
AD  - Department of Microbiology and Infection Control, Sexually Transmitted
      Infections, Research and Development, Statens Serum Institut, Copenhagen,
      Denmark.
FAU - Savicheva, Alevtina
AU  - Savicheva A
AD  - Laboratory of Microbiology, D.O. Ott Research Institute of Obstetrics,
      Gynaecology and Reproductology, St. Petersburg, Russia.
FAU - Rudneva, Natalia
AU  - Rudneva N
AD  - Tula Regional Clinic of Dermato-Venereology of the Ministry of Health of the Tula
      Region, Tula, Russia.
FAU - Sukhanova, Larisa
AU  - Sukhanova L
AD  - Tula Regional Clinic of Dermato-Venereology of the Ministry of Health of the Tula
      Region, Tula, Russia.
FAU - Kozlov, Roman
AU  - Kozlov R
AD  - Institute of Antimicrobial Chemotherapy, Smolensk State Medical University,
      Smolensk, Russia.
FAU - Guschin, Alexander
AU  - Guschin A
AD  - Laboratory of Molecular Diagnostics, Central Research Institute of Epidemiology, 
      Moscow, Russia.
FAU - Unemo, Magnus
AU  - Unemo M
AUID- ORCID: http://orcid.org/0000-0003-1710-2081
AD  - WHO Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory 
      Medicine, Faculty of Medicine and Health, Orebro University, Orebro, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20170413
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (DNA, Bacterial)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Macrolides)
RN  - 0 (RNA, Ribosomal, 23S)
SB  - IM
MH  - DNA, Bacterial/analysis
MH  - *Drug Resistance, Bacterial
MH  - Estonia
MH  - Female
MH  - Fluoroquinolones/*pharmacology/therapeutic use
MH  - Humans
MH  - Macrolides/*pharmacology/therapeutic use
MH  - Male
MH  - *Mutation
MH  - Mycoplasma Infections/*microbiology
MH  - Mycoplasma genitalium/*genetics/isolation & purification
MH  - Population Surveillance
MH  - Prevalence
MH  - RNA, Ribosomal, 23S/analysis
MH  - Russia
MH  - Sequence Analysis, DNA
EDAT- 2017/04/14 06:00
MHDA- 2017/04/21 06:00
CRDT- 2017/04/14 06:00
PHST- 2016/12/28 [received]
PHST- 2017/03/30 [accepted]
AID - 10.1371/journal.pone.0175763 [doi]
AID - PONE-D-16-51292 [pii]
PST - epublish
SO  - PLoS One. 2017 Apr 13;12(4):e0175763. doi: 10.1371/journal.pone.0175763.
      eCollection 2017.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>